Papers/PMID:31071081
N-acetylcysteine use among patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized trials.
PloS one2019The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
N-acetyl-L-cysteine — no detected effect on all-cause mortality
StrongEvidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding.FindingNull resultreplicated ×1“Results from 17 RCTs including 1,737 patients yielded a non-statistically significant difference between NAC and SoC on the reduction of mortality (RR 0.71, 95% CI 0.40 to 1.25; events (NAC:20/870, SoC:33/867); I2 = 0%; p = 0.23).”
Quoted verbatim from N-acetylcysteine use among patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized trials.. - Study
- meta-analysis
- Participants
- 1,737
- Population
- Adults undergoing on-pump or off-pump cardiac surgery, 17 randomised trials pooled, NAC added to standard of care versus standard of care with or without placebo; routes pooled (intravenous, cardioplegia, oral)
Effect 0.71 risk ratio, 95% CI 0.4 to 1.25
N-acetylcysteine use among patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized trials.2019PMID:31071081Permalink